NORTH WALES, Pa. – Teva Pharmaceuticals has released dexmethylphenidate hydrochloride extended-release capsules (CII), a medication for attention deficit hyperactivity disorder (ADHD), in a 20-mg strength.
Teva said Monday that its product is AB-rated and is a bioequivalent of Focalin XR extended-release capsules (CII) from Novartis.
With the addition of the new strength, Teva now offers dexmethylphenidate hydrochloride ER capsules in dosages of 5 mg, 10 mg, 15 mg, 20 mg, 30 mg and 40 mg.
“Our customers count on Teva for a continuous supply of new generic products,” stated Maureen Cavanaugh, senior vice president of U.S. generics sales and marketing at Teva. “With the launch of dexmethylphenidate hydrochloride extended-release capsules (CII) in a 20-mg strength, we add another quality product to our broad line of affordable generic pharmaceuticals.”
